TrialInternational journal of clinical oncology2025

A phase II study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).

Yohei Iimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.